Stocks Health care ABUS
NASDAQ · Health careArbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp brought in $181.7M of revenue over the twelve months to June 30, 2026, up 1,078.8% from a year earlier. Net income was $153.1M, a net margin of 84.2%. In fiscal 2025 capital spending exceeded operating cash flow by $39.6M. At June 30, 2026 it held $19.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Arbutus Biopharma Corp
- Net worth
- Arbutus Biopharma Corp has a market value (market cap) of $755.8M at the latest share price, and shareholders' equity of $258.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $14.1M (+128.2% year on year), with a net loss of $33.5M. Over the 12 months to June 30, 2026: revenue $181.7M, net income $153.1M.
- Cash flow
- In fiscal 2025 operations used $39.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arbutus Biopharma Corp's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Arbutus Biopharma Corp does
Arbutus Biopharma Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABUS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.1M | -$33.5M | -$0.17 | -$39.6M |
| 2024 | $6.2M | -$69.9M | -$0.38 | -$65M |
| 2023 | $18.1M | -$72.8M | -$0.44 | -$86.9M |
| 2022 | $39M | -$69.5M | -$0.46 | -$35.9M |
| 2021 | $11M | -$76.2M | -$0.83 | -$68.3M |
| 2020 | $6.9M | -$63.7M | -$1.00 | -$51.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ABUS ranks in Health care
Latest SEC filings
What Arbutus Biopharma Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 22, 2026Other event 8-K
- October 1, 2026Form SC TO-I/A filing SC TO-I/A
- September 30, 2026Form SC TO-I/A filing SC TO-I/A
- September 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 24, 2026Form SC TO-I filing SC TO-I
- August 21, 2026Form SC TO-C filing SC TO-C
- August 21, 2026Other event 8-K
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 91% to $1M versus the same quarter last year; diluted EPS -$0.03 versus $0.01.
Insider trades
What the people running Arbutus Biopharma Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 16 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Androski LindsayPresident and CEO, Director | Other change | 24,655 | $123.3K |
| October 1, 2026 | Sawhney RogerDirector | Other change | 17,142 | $85.7K |
| October 1, 2026 | Nguyen TuanChief Financial Officer | Other change | 48,081 | $240.4K |
| October 1, 2026 | Beardsley Robert ADirector | Other change | 17,948 | $89.7K |
| September 18, 2026 | Beardsley Robert ADirector | Exercised options | 52,533 | $168.1K |
| September 18, 2026 | Beardsley Robert ADirector | Exercised options | 78,800 | $334.1K |
| September 18, 2026 | Beardsley Robert ADirector | Shares withheld for tax | 99,057 | $502.2K |
| September 18, 2026 | Sawhney RogerDirector | Exercised options | 52,533 | $175.5K |
Who owns ABUS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Two Seas Capital LP13G, passive with 2 related filers | 9.4% | May 15, 2026 |
| Whitefort Capital Master Fund, LP13G, passive with 5 related filers | 8% | September 4, 2026 |
| BlackRock, Inc.13G, passive | 7.2% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 177 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Two Seas Capital LP | 19,095,583 | +538,040 |
| Morgan Stanley | 17,698,305 | -8,193,175 |
| Whitefort Capital Management, LP | 15,794,261 | +863,376 |
| BlackRock, Inc. | 13,766,071 | +799,125 |
| State Street Corp | 7,869,179 | +1,526,669 |
| Rubric Capital Management LP | 7,532,937 | +906,548 |
| Vanguard Capital Management LLC | 7,010,679 | +321,768 |
| Barclays PLC | 4,207,914 | -108,181 |
| Geode Capital Management, LLC | 4,117,691 | +345,885 |
| Goldman Sachs Group Inc | 3,506,802 | +2,406,368 |
| Bank of America Corp | 2,646,197 | +962,569 |
| BlackBarn Capital Partners LP | 2,500,000 | 0 |
| Legal & General Group Plc | 2,466,127 | +64,738 |
| Woodline Partners LP | 2,281,856 | +271,684 |
| Jefferies Financial Group Inc. | 1,711,672 | -182,395 |
| Nomura Holdings Inc | 1,637,081 | new |
| Vanguard Portfolio Management LLC | 1,541,458 | +149,434 |
| Charles Schwab Investment Management Inc | 1,431,218 | +30,061 |
| Northern Trust Corp | 1,419,024 | +141,165 |
| Osaic Holdings, Inc. | 1,347,866 | -261 |
Insiders
4 insiders reported holding 187,575 shares in total, about $716.5K at the last price.
| Holder | Shares |
|---|---|
| Nguyen TuanChief Financial Officer | 111,882 |
| Androski LindsayPresident and CEO, Director | 47,682 |
| Beardsley Robert ADirector | 14,328 |
| Sawhney RogerDirector | 13,683 |
Questions about ABUS
What does Arbutus Biopharma Corp do?
Arbutus Biopharma Corp is a company in the Health care sector, listed on NASDAQ as ABUS. Its shares trade on NASDAQ under the ticker ABUS.
What is Arbutus Biopharma Corp's net worth?
Arbutus Biopharma Corp has a market value (market cap) of $755.8M at the latest share price, and shareholders' equity of $258.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arbutus Biopharma Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $153.1M on revenue of $181.7M, a net margin of 84.2%.
How much revenue does Arbutus Biopharma Corp make?
Over the twelve months to June 30, 2026 Arbutus Biopharma Corp reported revenue of $181.7M. That is 1,078.8% more than a year earlier.
When did Arbutus Biopharma Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 27, 2026.
When is Arbutus Biopharma Corp's next earnings report?
Arbutus Biopharma Corp's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ABUS with
Follow ABUS
Get an email when Arbutus Biopharma Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arbutus Biopharma Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.